Richard Thomas Beresis

This inventor holds 27 USPTO granted patents and 11 published patent applications and 15 EPO patents, primarily in Neuroactive Steroids. Top assignees: Sage Therapeutics, Inc., Merck Sharp + Dohme Corp., Merck Sharp + Dohme B.v.. Active years: 2015-2025.

USPTO Granted Patents = 27 (Patent Applications = 11)

% Patents Active = 100.0

EPO Patents = 15 (Patent Applications = 17)

Average Co-Inventor Count = 6.2

ph-index = 12

Forward Citations = 371(Granted Patents)

Location History:

Shanghai, KR (2018)
Shanghai, CN (2015 - 2024)

Company Filing History:

15 out of 99

Sage Therapeutics, Inc.

patents

11 out of 2,405

Merck Sharp + Dohme Corp.

patents

3 out of 55

Merck Sharp + Dohme B.v.

patents

4. 1 out of 1

Sage Therpeutics, Inc.

patent

where one patent can have more than one assignee

Years Active: 2015-2025

Loading Chart...

Areas of Expertise:

Neuroactive Steroids

CNS Disorders

RORgammaT Inhibitors

19-nor Compounds

Steroid Chemistry

Heteroaryl Compounds

Mineralocorticoid Antagonists

Cycloalkyl Compounds

Indole Compounds

Pyrazolyl Steroids

Benzoic Acid Compounds

Aminocycloalkyl Compounds

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12201640 - 19-nor C3,3-disubstituted C21-n-pyrazolyl steroids and methods of use thereof (2025-01-21),

2. 11945836 - Compositions and methods for treating CNS disorders (2024-04-02),

3. 11912737 - 19-nor neuroactive steroids and methods of use thereof (2024-02-27),

4. 11344563 - 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof (2022-05-31),

5. 11261211 - 19-NOR neuroactive steroids and methods of use thereof (2022-03-01),

6. 11241446 - 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof (2022-02-08),

7. 10822370 - 19-nor neuroactive steroids and methods of use thereof (2020-11-03),

8. 10774108 - Compositions and methods for treating CNS disorders (2020-09-15),

9. 10391106 - 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof (2019-08-27),

10. 10377790 - 19-nor neuroactive steroids and methods of use thereof (2019-08-13),

11. 10342810 - 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof (2019-07-09),

12. 10196354 - 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof (2019-02-05),

13. 10172871 - 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof (2019-01-08),

14. 10023606 - 19-nor neuroactive steroids and methods of use thereof (2018-07-17),

15. 9884043 - RORgammaT inhibitors (2018-02-06),

Title: **Richard Thomas Beresis: Innovator in Neuroactive Steroids**

Introduction

Richard Thomas Beresis is an accomplished inventor based in Shanghai, China, known for his significant contributions to the field of pharmacology and neuroactive steroids. With a remarkable portfolio of 27 patents, Beresis has made strides in developing innovative solutions for various central nervous system (CNS) disorders.

Latest Patents

Among his latest patents, Beresis has developed compounds including "19-nor C3,3-disubstituted C21-n-pyrazolyl steroids and methods of use thereof." These compounds are designed to address multiple CNS-related conditions such as sleep disorders, mood disorders, and traumatic brain injury. Furthermore, his patent on "Compositions and methods for treating CNS disorders" introduces neuroactive steroids that function as GABA modulators, offering potential therapeutic benefits for sedation and anesthesia.

Career Highlights

Richard has held prominent positions in noteworthy companies such as Sage Therapeutics, Inc. and Merck Sharp & Dohme Corporation. His experience in these pharmaceutical firms has been pivotal in advancing his research and development efforts in neuroactive steroid therapies.

Collaborations

Throughout his career, Beresis has collaborated with distinguished coworkers including Albert Jean Robichaud and Gabriel Martinez Botella. These partnerships have facilitated innovative research and the successful development of groundbreaking pharmaceutical solutions.

Conclusion

In summary, Richard Thomas Beresis stands out as a key inventor in the realm of neuroactive steroids, with his advancements promising significant impact on the treatment of complex CNS disorders. His ongoing work and patent portfolio continue to propel the field forward, offering hope for many individuals affected by these conditions.